ArticleFrontiers in pharmacology2025
Different degrees of expression of pulmonary fibrosis signs with intratracheal administration of bleomycin at different doses in male SD rats (a study aimed at helping to select the optimal bleomycin dose for modeling pulmonary fibrosis).
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioresponsive gelatin-coated silk fibroin nanoparticles enhance roxadustat therapy in experimental pulmonary fibrosis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary fibrosis (PF) is a life-threatening lung disease. PF develops under the influence of various damaging agents. To study new therapeutic strategies, a PF model with intratracheal administration of bleomycin (BLM) is used. Methods: We studied the effect of different doses of BLM. The study was performed on male SD rats. BLM was administrated at doses of 0.5, 1.5, 2.5, 3, and 5 mg/kg. Animals were observed for 21 days for the following parameters: the overall health status, body weight gain, and external respiratory function. On the 22nd day, the lung weight, cellular composition of the bronchoalveolar fluid (BALF), and hydroxyproline content were determined, and the degree of lung fibrosis was histologically assessed. Results: With an increase in the BLM dose, the overall health status deteriorates, the function of external respiration worsens, BALF neutrophilic infiltration increases, and PF severity increases. The least marked PF manifestations were observed after the administration of BLM at a dose of 0.5 mg/kg, and the most marked manifestations were observed after the administration of BLM at a dose of 5 mg/kg. Conclusion: Results obtained in the study demonstrate a dose-dependent effect of BLM on the PF severity, which provides information that will help select BLM dose suitable for obtaining desired degree of PF in animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.